Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma

Divya Gupta, Marc J. Gunter, Kathleen Yang, Stephen Lee, Lisa Zuckerwise, Lee May Chen, Gary L. Goldberg, Gloria S. Huang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Hypothesis: Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC). Methods: All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ 2 tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling. Results: Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r 2 = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77). Conclusions: Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.

Original languageEnglish (US)
Pages (from-to)529-534
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume21
Issue number3
DOIs
StatePublished - Apr 2011

Fingerprint

Papillary Carcinoma
Biomarkers
Serum
Recurrence
Lymph Nodes
Neoplasm Metastasis
Survival
Survival Analysis
Multivariate Analysis
Confidence Intervals

Keywords

  • Biomarker
  • CA125
  • UPSC
  • Uterine papillary serous carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. / Gupta, Divya; Gunter, Marc J.; Yang, Kathleen; Lee, Stephen; Zuckerwise, Lisa; Chen, Lee May; Goldberg, Gary L.; Huang, Gloria S.

In: International Journal of Gynecological Cancer, Vol. 21, No. 3, 04.2011, p. 529-534.

Research output: Contribution to journalArticle

Gupta, D, Gunter, MJ, Yang, K, Lee, S, Zuckerwise, L, Chen, LM, Goldberg, GL & Huang, GS 2011, 'Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma', International Journal of Gynecological Cancer, vol. 21, no. 3, pp. 529-534. https://doi.org/10.1097/IGC.0b013e31821091b5
Gupta, Divya ; Gunter, Marc J. ; Yang, Kathleen ; Lee, Stephen ; Zuckerwise, Lisa ; Chen, Lee May ; Goldberg, Gary L. ; Huang, Gloria S. / Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma. In: International Journal of Gynecological Cancer. 2011 ; Vol. 21, No. 3. pp. 529-534.
@article{b54f943409244c67975a74ab3c65112f,
title = "Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma",
abstract = "Hypothesis: Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC). Methods: All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ 2 tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling. Results: Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17{\%}) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29{\%}) patients experienced disease recurrence and 10 (19{\%}) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r 2 = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95{\%} confidence interval, 0.55-4.77). Conclusions: Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.",
keywords = "Biomarker, CA125, UPSC, Uterine papillary serous carcinoma",
author = "Divya Gupta and Gunter, {Marc J.} and Kathleen Yang and Stephen Lee and Lisa Zuckerwise and Chen, {Lee May} and Goldberg, {Gary L.} and Huang, {Gloria S.}",
year = "2011",
month = "4",
doi = "10.1097/IGC.0b013e31821091b5",
language = "English (US)",
volume = "21",
pages = "529--534",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Performance of serum CA125 as a prognostic biomarker in patients with uterine papillary serous carcinoma

AU - Gupta, Divya

AU - Gunter, Marc J.

AU - Yang, Kathleen

AU - Lee, Stephen

AU - Zuckerwise, Lisa

AU - Chen, Lee May

AU - Goldberg, Gary L.

AU - Huang, Gloria S.

PY - 2011/4

Y1 - 2011/4

N2 - Hypothesis: Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC). Methods: All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ 2 tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling. Results: Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r 2 = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77). Conclusions: Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.

AB - Hypothesis: Serum CA125 is a potential biomarker for metastatic disease and recurrence in patients with uterine papillary serous carcinoma (UPSC). Methods: All patients with UPSC who had preoperative CA125 measurement and surgical staging between 1998 and 2008 at the participating institutions were included in this analysis (N = 52). Data were extracted from patients' records. Fisher exact and χ 2 tests were used to assess the association of CA125 levels with clinical and pathological variables. The correlation between CA125 levels (high/low) and lymph node metastases (positive/negative) was evaluated using Spearman correlation coefficients. The association of CA125 elevation with recurrence-free survival was assessed using Cox proportional hazards regression modeling. Results: Preoperative CA125 elevation (>30 U/mL) was observed in 9 (17%) patients and was associated with advanced International Federation of Gynecologists and Obstetricians (FIGO) stage III/IV disease (P = 0.002), lymph node involvement (P = 0.007), and presence of omental metastases (P = 0.001). Disease recurrence and survival data were available for 51 of the 52 patients. During a mean follow-up time of 36 months, 15 (29%) patients experienced disease recurrence and 10 (19%) patients died. There was a moderate positive correlation between CA125 levels and lymph node metastases (r 2 = 0.39). On multivariate survival analysis, an elevated CA125 level compared to nonelevated CA-125 was not associated with disease recurrence (hazard ratio, 1.61; 95% confidence interval, 0.55-4.77). Conclusions: Preoperative CA125 levels were significantly associated with metastatic disease in patients with UPSC. However, in this study of surgically staged UPSC patients, preoperative CA125 elevation was not an independent predictor of disease recurrence.

KW - Biomarker

KW - CA125

KW - UPSC

KW - Uterine papillary serous carcinoma

UR - http://www.scopus.com/inward/record.url?scp=80051609144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051609144&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e31821091b5

DO - 10.1097/IGC.0b013e31821091b5

M3 - Article

VL - 21

SP - 529

EP - 534

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -